Tadao Ishida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tadao Ishida has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Shinsuke Iida
Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan
11 shared publications - Hiroshi Handa
Department of Hematology Gunma University Graduate School of Medicine Maebashi Gunma Japan
4 shared publications Hirohiko Shibayama
Department of Hematology National Hospital Organization Osaka National Hospital Osaka Japan
3 shared publications- Junya Kuroda
Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan
3 shared publications Kazutaka Sunami
15Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
3 shared publicationsKensuke Aida
Janssen Pharm KK, R&D, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Cancer Science
Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH ‐ MM ‐15 Study
T(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associated with other cytogenetic risk categories. In a post hoc analysis of the prospective JSH‐MM‐15 study, we investigated the prognosis of newly diagnosed MM patients to identify prognostic features unique to t(11;14)‐positive cases and to evaluate treatment factors influencing outcomes. Among 482 patients evaluated for t(11;14), 131 (27%) were positive. Overall survival (OS) in t(11;14)‐positive patients was intermediate between standard‐ and high‐risk groups, whereas progression‐free survival (PFS) was comparable to that of high‐risk cases. Deep response rates, including ≥ complete response (CR)/stringent CR and ≥ very good partial response, were lower in t(11;14)‐positive MM than in other risk groups, and these responses were not associated with survival in t(11;14)‐positive cases, in contrast to t(11;14)‐negative MM. Compared with t(11;14)‐negative MM, t(11;14)‐positive patients more frequently expressed CD20 and less frequently expressed CD56 on myeloma cells. Exploratory analyses showed that, despite higher ≥ CR rates, OS was worse in patients with CD20‐negative/CD56‐negative tumors among t(11;14)‐positive MM. Among CD20‐positive patients, PI‐containing regimens were associated with better OS, although no significant PFS benefit was observed. These findings support the biological and clinical heterogeneity of t(11;14)‐positive MM and highlight the need for prospective validation of subgroup‐specific treatment outcomes.
- 15 October 2026
- Published by Wiley in Cancer Science
Open AccessDistinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH ‐ MM ‐15 Study
T(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associated with other cytogenetic risk categories. In a post hoc analysis of the prospective JSH‐MM‐15 study, we investigated the prognosis of newly diagnosed MM patients to identify prognostic features unique to t(11;14)‐positive cases and to evaluate treatment factors influencing outcomes. Among 482 patients evaluated for t(11;14), 131 (27%) were positive. Overall survival (OS) in t(11;14)‐positive patients was intermediate between standard‐ and high‐risk groups, whereas progression‐free survival (PFS) was comparable to that of high‐risk cases. Deep response rates, including ≥ complete response (CR)/stringent CR and ≥ very good partial response, were lower in t(11;14)‐positive MM than in other risk groups, and these responses were not associated with survival in t(11;14)‐positive cases, in contrast to t(11;14)‐negative MM. Compared with t(11;14)‐negative MM, t(11;14)‐positive patients more frequently expressed CD20 and less frequently expressed CD56 on myeloma cells. Exploratory analyses showed that, despite higher ≥ CR rates, OS was worse in patients with CD20‐negative/CD56‐negative tumors among t(11;14)‐positive MM. Among CD20‐positive patients, PI‐containing regimens were associated with better OS, although no significant PFS benefit was observed. These findings support the biological and clinical heterogeneity of t(11;14)‐positive MM and highlight the need for prospective validation of subgroup‐specific treatment outcomes.
- 9 July 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (9) , 623-631.e1
Pre-CAR-HEMATOTOX at leukapheresis predicts delayed platelet recovery after idecabtagene vicleucel in multiple myeloma
- 9 July 2026
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (9) , 623-631.e1
Pre-CAR-HEMATOTOX at leukapheresis predicts delayed platelet recovery after idecabtagene vicleucel in multiple myeloma
- Open Access
- 4 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2760-2769
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study
Quadruplet therapy with Isa-VRd (isatuximab, Velcade [bortezomib], Revlimid [lenalidomide], and dexamethasone) followed by Isa-Rd in the randomized phase 3 IMROZ study provided a significant progression-free survival benefit to transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). In the primary analysis, more Isa-VRd/Isa-Rd–treated patients achieved minimal residual disease (MRD) negativity and MRD-negative complete response (CR) at any time point than patients receiving VRd followed by Rd. Here, we report landmark analysis results of MRD negativity over time and its impact on clinical outcomes in IMROZ. Treatment with Isa-VRd/Isa-Rd led to deeper responses, with higher rates of MRD negativity and MRD-negative CR at the end of induction and during maintenance vs VRd/Rd, up to 60 months of follow-up. Benefit with Isa-VRd/Isa-Rd was observed across key patient subgroups, including older (>70 years) and frail patients. Time to progression (TTP) was significantly prolonged with Isa-VRd/Isa-Rd vs VRd/Rd in patients who converted from MRD negative to MRD positive at any time point. In a landmark analysis of the time of conversion to MRD positivity, TTP in patients who converted from MRD negative at the end of induction to MRD positive also favored Isa-VRd/Isa-Rd. Evaluating MRD status of patients at >1 time point may therefore be useful to support decisions on treatment selection and treatment continuation/discontinuation. Our findings on the degree of MRD negativity and MRD-negative CR benefit achieved during induction and maintenance by patients receiving Isa-VRd/Isa-Rd vs VRd/Rd extend the IMROZ primary analyses and further support Isa-VRd as standard of care for frontline treatment of transplant-ineligible patients with NDMM. This trial was registered at www.clinicaltrials.gov as #NCT03319667.
- 4 June 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2760-2769
Open AccessIsatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study
Quadruplet therapy with Isa-VRd (isatuximab, Velcade [bortezomib], Revlimid [lenalidomide], and dexamethasone) followed by Isa-Rd in the randomized phase 3 IMROZ study provided a significant progression-free survival benefit to transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). In the primary analysis, more Isa-VRd/Isa-Rd–treated patients achieved minimal residual disease (MRD) negativity and MRD-negative complete response (CR) at any time point than patients receiving VRd followed by Rd. Here, we report landmark analysis results of MRD negativity over time and its impact on clinical outcomes in IMROZ. Treatment with Isa-VRd/Isa-Rd led to deeper responses, with higher rates of MRD negativity and MRD-negative CR at the end of induction and during maintenance vs VRd/Rd, up to 60 months of follow-up. Benefit with Isa-VRd/Isa-Rd was observed across key patient subgroups, including older (>70 years) and frail patients. Time to progression (TTP) was significantly prolonged with Isa-VRd/Isa-Rd vs VRd/Rd in patients who converted from MRD negative to MRD positive at any time point. In a landmark analysis of the time of conversion to MRD positivity, TTP in patients who converted from MRD negative at the end of induction to MRD positive also favored Isa-VRd/Isa-Rd. Evaluating MRD status of patients at >1 time point may therefore be useful to support decisions on treatment selection and treatment continuation/discontinuation. Our findings on the degree of MRD negativity and MRD-negative CR benefit achieved during induction and maintenance by patients receiving Isa-VRd/Isa-Rd vs VRd/Rd extend the IMROZ primary analyses and further support Isa-VRd as standard of care for frontline treatment of transplant-ineligible patients with NDMM. This trial was registered at www.clinicaltrials.gov as #NCT03319667.
- Open Access
- 23 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database
Background: Early diagnosis of primary or light chain (AL) amyloidosis is crucial for initiating appropriate therapeutic interventions. However, diagnosis is getting delayed (several months-to-years) in clinical practice. Objective: To investigate the real-world patterns of clinical procedures until initial diagnosis of AL amyloidosis in Japan. Design: Retrospective longitudinal, observational cohort study. Methods: This study included adults with AL amyloidosis using Medical Data Vision claims database (2003–2022). The primary endpoint was time from initial hospital visit until confirmed AL amyloidosis diagnosis. Symptoms, lab tests, and medical department visits until diagnosis, and mortality were analyzed. Results: Overall, 323 patients with AL amyloidosis were included (median age: 73.0 years). Median time to confirmed diagnosis was 81.5 days; reported longer in patients aged ⩾65 years versus <65 years, and Charlson Comorbidity Index ⩾4 than 1 year). Conclusion: These real-world data from Japanese AL amyloidosis patients are crucial for early and effective treatment, leading to better prognosis.
- 23 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessA retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database
Background: Early diagnosis of primary or light chain (AL) amyloidosis is crucial for initiating appropriate therapeutic interventions. However, diagnosis is getting delayed (several months-to-years) in clinical practice. Objective: To investigate the real-world patterns of clinical procedures until initial diagnosis of AL amyloidosis in Japan. Design: Retrospective longitudinal, observational cohort study. Methods: This study included adults with AL amyloidosis using Medical Data Vision claims database (2003–2022). The primary endpoint was time from initial hospital visit until confirmed AL amyloidosis diagnosis. Symptoms, lab tests, and medical department visits until diagnosis, and mortality were analyzed. Results: Overall, 323 patients with AL amyloidosis were included (median age: 73.0 years). Median time to confirmed diagnosis was 81.5 days; reported longer in patients aged ⩾65 years versus <65 years, and Charlson Comorbidity Index ⩾4 than 1 year). Conclusion: These real-world data from Japanese AL amyloidosis patients are crucial for early and effective treatment, leading to better prognosis.
- Open Access
Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory multiple myeloma (MM), with BCMA-directed products demonstrating unprecedented response rates in heavily pretreated patients. Despite these advances, variabilities in response durability, treatment-related toxicities, and the emergence of resistance underscore the need for strategies that extend beyond CAR construct design alone. Accumulating evidence has indicated that the therapeutic outcomes of this approach are determined by a complex interplay between tumor burden, antigen dynamics, CAR T-cell functional fitness, and host immune context at the time of infusion. Effector-to-target balance and antigen load, in particular, have emerged as modifiable biological determinants of efficacy and safety, with pre-infusion disease control and response to bridging therapy exerting a profound influence on post-infusion CAR T-cell expansion, persistence, and clinical outcomes. Soluble BCMA (sBCMA) has also gained increasing attention as a practical biomarker that integrates tumor burden and antigen dynamics to facilitate the biologically informed optimization of treatment timing and patient selection. In addition to tumor- and antigen-related factors, the intrinsic properties of CAR T-cell products—including the spatial organization and clustering of CAR molecules on the T-cell surface—represent an additional layer of biological determinants that correlate with treatment responses. The quantitative functional assessment of CAR T-cell products may complement conventional clinical and tumor-based biomarkers and improve the prediction of therapeutic potency prior to infusion. This review summarizes recent advances in CAR T-cell therapy for treating MM, focusing on key mechanisms of resistance, the optimization of pre-infusion disease control, the integration of biological markers into clinical decision-making, and emerging combinations and sequential strategies. We also propose a design-oriented and patient-centered framework that integrates CAR engineering with disease biology and host immune factors to enhance the consistency, durability, and safety of CAR T-cell therapy. Such biologically guided optimization strategies will likely prove critical for fully realizing the transformative potential of CAR T-cell therapy across the evolving treatment continuum of MM.
Open AccessDeterminants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory multiple myeloma (MM), with BCMA-directed products demonstrating unprecedented response rates in heavily pretreated patients. Despite these advances, variabilities in response durability, treatment-related toxicities, and the emergence of resistance underscore the need for strategies that extend beyond CAR construct design alone. Accumulating evidence has indicated that the therapeutic outcomes of this approach are determined by a complex interplay between tumor burden, antigen dynamics, CAR T-cell functional fitness, and host immune context at the time of infusion. Effector-to-target balance and antigen load, in particular, have emerged as modifiable biological determinants of efficacy and safety, with pre-infusion disease control and response to bridging therapy exerting a profound influence on post-infusion CAR T-cell expansion, persistence, and clinical outcomes. Soluble BCMA (sBCMA) has also gained increasing attention as a practical biomarker that integrates tumor burden and antigen dynamics to facilitate the biologically informed optimization of treatment timing and patient selection. In addition to tumor- and antigen-related factors, the intrinsic properties of CAR T-cell products—including the spatial organization and clustering of CAR molecules on the T-cell surface—represent an additional layer of biological determinants that correlate with treatment responses. The quantitative functional assessment of CAR T-cell products may complement conventional clinical and tumor-based biomarkers and improve the prediction of therapeutic potency prior to infusion. This review summarizes recent advances in CAR T-cell therapy for treating MM, focusing on key mechanisms of resistance, the optimization of pre-infusion disease control, the integration of biological markers into clinical decision-making, and emerging combinations and sequential strategies. We also propose a design-oriented and patient-centered framework that integrates CAR engineering with disease biology and host immune factors to enhance the consistency, durability, and safety of CAR T-cell therapy. Such biologically guided optimization strategies will likely prove critical for fully realizing the transformative potential of CAR T-cell therapy across the evolving treatment continuum of MM.
- Open Access
- 19 February 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e75586
Assessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database
Background: With the availability of newer therapies, the duration of therapy (DoT) shortens with each increasing line of treatment in Japanese patients with multiple myeloma (MM). Objective: This study aimed to identify factors that shorten DoT in patients with MM using a machine learning (ML) procedure from the Medical Data Vision (MDV) database. Methods: This nationwide, retrospective observational real-world study was conducted using anonymized patient data from the MDV claims database from 2003 to 2022. Patients (≥18 y) with transplant-ineligible newly diagnosed MM (continued first line therapy), or relapsed or refractory MM (continued second or third line therapies) were included. To identify important predictive factors, an explainable deep learning model was created using 647 extracted variables (continuous, binary, and nominal categorical) from the MDV database, and the extracted data were used to train ML algorithms to build point-wise linear (PWL) models for predicting DoT. Predictive performance of the PWL model was compared with the elastic net (regularized logistic regression) and the extreme gradient boosting models, and calculated by area under the curve and evaluated by 10-fold double cross-validation. A clustering analysis (k-means method) of 4848 individual samples assessed the relationship between each sample and DoT (3, 6, and 12 months). The characteristics of clusters and sample features belonging to each cluster during and after treatment were studied. Results: Overall, 2762 (4848 individual samples) patients were evaluated (mean age 69.6, SD 11.8 years; 1450/2762, 52.5% male). The area under the curve score of the PWL model to predict DoT at 3, 6, and 12 months was 0.61, 0.64, and 0.66, respectively. Based on the similarity of coefficients of regression models, samples were categorized into 2 clusters (clusters A and B) at DoT of 3 months, 3 clusters (clusters A, B, and C) at 6 months, and 12 months (clusters A, B, and C). Cluster B versus cluster A (at 3 months) and cluster C versus cluster A and B (at 6 and 12 months) had a significantly (P<.01) higher pretreatment Charlson Comorbidity Index. They also showed a lower median of prediction probability. At 3 months in cluster B and at 6 and 12 months in cluster C, the use of immunomodulatory drugs for MM treatment was significantly higher in patients who met predicted DoT at each threshold versus those who did not. Additionally, the use of aspirin was significantly higher in cluster B and cluster C at 3 and 6 months, respectively. Conclusions: Applying ML techniques using the PWL model yielded efficient results to understand trends associated with treatment and characteristics of Japanese patients with MM whose DoT were shortened. The study demonstrated that patients’ disease status and management-related factors, including use of immunomodulatory drugs and management of thromboprophylaxis, may be associated with DoT length.
- 19 February 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12, e75586
Open AccessAssessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database
Background: With the availability of newer therapies, the duration of therapy (DoT) shortens with each increasing line of treatment in Japanese patients with multiple myeloma (MM). Objective: This study aimed to identify factors that shorten DoT in patients with MM using a machine learning (ML) procedure from the Medical Data Vision (MDV) database. Methods: This nationwide, retrospective observational real-world study was conducted using anonymized patient data from the MDV claims database from 2003 to 2022. Patients (≥18 y) with transplant-ineligible newly diagnosed MM (continued first line therapy), or relapsed or refractory MM (continued second or third line therapies) were included. To identify important predictive factors, an explainable deep learning model was created using 647 extracted variables (continuous, binary, and nominal categorical) from the MDV database, and the extracted data were used to train ML algorithms to build point-wise linear (PWL) models for predicting DoT. Predictive performance of the PWL model was compared with the elastic net (regularized logistic regression) and the extreme gradient boosting models, and calculated by area under the curve and evaluated by 10-fold double cross-validation. A clustering analysis (k-means method) of 4848 individual samples assessed the relationship between each sample and DoT (3, 6, and 12 months). The characteristics of clusters and sample features belonging to each cluster during and after treatment were studied. Results: Overall, 2762 (4848 individual samples) patients were evaluated (mean age 69.6, SD 11.8 years; 1450/2762, 52.5% male). The area under the curve score of the PWL model to predict DoT at 3, 6, and 12 months was 0.61, 0.64, and 0.66, respectively. Based on the similarity of coefficients of regression models, samples were categorized into 2 clusters (clusters A and B) at DoT of 3 months, 3 clusters (clusters A, B, and C) at 6 months, and 12 months (clusters A, B, and C). Cluster B versus cluster A (at 3 months) and cluster C versus cluster A and B (at 6 and 12 months) had a significantly (P<.01) higher pretreatment Charlson Comorbidity Index. They also showed a lower median of prediction probability. At 3 months in cluster B and at 6 and 12 months in cluster C, the use of immunomodulatory drugs for MM treatment was significantly higher in patients who met predicted DoT at each threshold versus those who did not. Additionally, the use of aspirin was significantly higher in cluster B and cluster C at 3 and 6 months, respectively. Conclusions: Applying ML techniques using the PWL model yielded efficient results to understand trends associated with treatment and characteristics of Japanese patients with MM whose DoT were shortened. The study demonstrated that patients’ disease status and management-related factors, including use of immunomodulatory drugs and management of thromboprophylaxis, may be associated with DoT length.
- Open Access
Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti–B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody–drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome management, and the bispecific antibody emicizumab has transformed prophylaxis in hemophilia A. Furthermore, novel antibody formats such as the trifunctional anti-CD38 × CD3 antibody (Tri-31C2) exhibit enhanced anti-myeloma activity compared to chimeric CD38 antibodies, underscoring the future potential of T-cell–redirecting designs. This review summarizes key developments in therapeutic antibodies for hematological disorders, their action mechanisms, and emerging strategies to further optimize their efficacy and safety.
Open AccessTherapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders
Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti–B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody–drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome management, and the bispecific antibody emicizumab has transformed prophylaxis in hemophilia A. Furthermore, novel antibody formats such as the trifunctional anti-CD38 × CD3 antibody (Tri-31C2) exhibit enhanced anti-myeloma activity compared to chimeric CD38 antibodies, underscoring the future potential of T-cell–redirecting designs. This review summarizes key developments in therapeutic antibodies for hematological disorders, their action mechanisms, and emerging strategies to further optimize their efficacy and safety.
- Open Access
- 16 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (18) , 4716-4719
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?
- 16 September 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (18) , 4716-4719
Open AccessCan baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?
- 3 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (22) , 2527-2537
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
PURPOSE: To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166 ) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (MM), to our knowledge, the first phase III MM trial using an on-body injector (OBI). METHODS: Patients with ≥1 prior line of therapy were randomly assigned 1:1 to Isa OBI (1,400 mg) or IV (10 mg/kg) once weekly in cycle (C)1 and then every 2 weeks, plus pomalidomide (4 mg once daily, day [D]1-21) and dexamethasone (40 mg once weekly [age ≥75: 20 mg]) and treated until progression, unacceptable toxicity, or patient request. Coprimary end points were overall response rate (ORR; noninferiority margin, 0.839) and Isa C trough (C6D1 predose; noninferiority margin, 0.8). Noninferiority of OBI versus IV was demonstrated if both coprimary end points achieved noninferiority. RESULTS: IRAKLIA randomly assigned 531 patients (OBI, n=263; IV, n=268). After 12-month median follow-up, the ORR was 71.1% (OBI) and 70.5% (IV; relative risk, 1.008 [95% CI, 0.903 to 1.126]; lower CI exceeded noninferiority margin). The mean (standard deviation) C6D1 C trough was 499 (259) μg/mL (OBI) and 340 (169) μg/mL (IV). The C trough geometric mean ratio (90% CI) was 1.532 (1.316 to 1.784); lower CI exceeded noninferiority margin. Grade ≥3 treatment-emergent adverse event incidences were 81.7% (OBI) and 76.1% (IV); infusion reaction incidences were 1.5% and 25.0%. Injection site reactions occurred in 0.4% of OBI injections (all grade 1-2); 99.9% of injections completed without interruption. CONCLUSION: IRAKLIA demonstrated efficacy and pharmacokinetic noninferiority between Isa OBI and IV. No unexpected safety signal was observed, with excellent local tolerability of Isa OBI. Efficacy and safety were comparable with Isa IV in ICARIA-MM, except the lower OBI infusion reaction rate. These results support potential use of the OBI, designed to improve practice efficiency.
- 3 June 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (22) , 2527-2537
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
PURPOSE: To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166 ) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (MM), to our knowledge, the first phase III MM trial using an on-body injector (OBI). METHODS: Patients with ≥1 prior line of therapy were randomly assigned 1:1 to Isa OBI (1,400 mg) or IV (10 mg/kg) once weekly in cycle (C)1 and then every 2 weeks, plus pomalidomide (4 mg once daily, day [D]1-21) and dexamethasone (40 mg once weekly [age ≥75: 20 mg]) and treated until progression, unacceptable toxicity, or patient request. Coprimary end points were overall response rate (ORR; noninferiority margin, 0.839) and Isa C trough (C6D1 predose; noninferiority margin, 0.8). Noninferiority of OBI versus IV was demonstrated if both coprimary end points achieved noninferiority. RESULTS: IRAKLIA randomly assigned 531 patients (OBI, n=263; IV, n=268). After 12-month median follow-up, the ORR was 71.1% (OBI) and 70.5% (IV; relative risk, 1.008 [95% CI, 0.903 to 1.126]; lower CI exceeded noninferiority margin). The mean (standard deviation) C6D1 C trough was 499 (259) μg/mL (OBI) and 340 (169) μg/mL (IV). The C trough geometric mean ratio (90% CI) was 1.532 (1.316 to 1.784); lower CI exceeded noninferiority margin. Grade ≥3 treatment-emergent adverse event incidences were 81.7% (OBI) and 76.1% (IV); infusion reaction incidences were 1.5% and 25.0%. Injection site reactions occurred in 0.4% of OBI injections (all grade 1-2); 99.9% of injections completed without interruption. CONCLUSION: IRAKLIA demonstrated efficacy and pharmacokinetic noninferiority between Isa OBI and IV. No unexpected safety signal was observed, with excellent local tolerability of Isa OBI. Efficacy and safety were comparable with Isa IV in ICARIA-MM, except the lower OBI infusion reaction rate. These results support potential use of the OBI, designed to improve practice efficiency.
- Open Access
- 9 May 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (3) , 421-433
Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM
The bispecific antibody talquetamab demonstrated substantial responses in heavily pretreated relapsed or refractory multiple myeloma (RRMM) in the global phase 1/2 MonumenTAL-1 study. This study, evaluated the safety and efficacy of talquetamab in Japanese patients with RRMM pretreated with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody. The primary endpoints were frequency and type of treatment-emergent adverse events (TEAEs) and serious AEs including dose-limiting toxicity (DLT). The secondary endpoints were overall response (ORR; partial response or better), duration of, and time to response. At data cutoff, 15 patients had received subcutaneous talquetamab at three doses (Cohort 1: 135 µg/kg weekly [QW, n = 4]; Cohort 2: 400 µg/kg [QW, n = 5]; Cohort 3: 800 µg/kg [Q2W, n = 6]). No DLTs, deaths, or AE-related dose reductions/treatment discontinuation were observed. Common TEAEs were neutropenia (60.0%), lymphopenia (53.3%), and CRS (46.7%). TEAEs of clinical interest (all Grade ≤ 2) were dysgeusia, skin toxicity, nail disorder, and dry mouth. With an overall median follow-up of 9.0 months, the ORR was 60.0% (95% confidence interval 32.3%, 83.7%). Talquetamab showed substantial responses in Japanese patients with RRMM, consistent with the global MonumenTAL-1 study, supporting its potential as a new standard of care for Japanese RRMM patients.
- 9 May 2025
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (3) , 421-433
Open AccessPhase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM
The bispecific antibody talquetamab demonstrated substantial responses in heavily pretreated relapsed or refractory multiple myeloma (RRMM) in the global phase 1/2 MonumenTAL-1 study. This study, evaluated the safety and efficacy of talquetamab in Japanese patients with RRMM pretreated with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody. The primary endpoints were frequency and type of treatment-emergent adverse events (TEAEs) and serious AEs including dose-limiting toxicity (DLT). The secondary endpoints were overall response (ORR; partial response or better), duration of, and time to response. At data cutoff, 15 patients had received subcutaneous talquetamab at three doses (Cohort 1: 135 µg/kg weekly [QW, n = 4]; Cohort 2: 400 µg/kg [QW, n = 5]; Cohort 3: 800 µg/kg [Q2W, n = 6]). No DLTs, deaths, or AE-related dose reductions/treatment discontinuation were observed. Common TEAEs were neutropenia (60.0%), lymphopenia (53.3%), and CRS (46.7%). TEAEs of clinical interest (all Grade ≤ 2) were dysgeusia, skin toxicity, nail disorder, and dry mouth. With an overall median follow-up of 9.0 months, the ORR was 60.0% (95% confidence interval 32.3%, 83.7%). Talquetamab showed substantial responses in Japanese patients with RRMM, consistent with the global MonumenTAL-1 study, supporting its potential as a new standard of care for Japanese RRMM patients.